Arielle Heeke is a Hematology physician affiliated with Levine Cancer Institute. OpenAlex indexes 50 publications with 902 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Europe GmbHProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
92.2%Aromatase Inhibitor64.7%Letrozole47%Anastrozole42%Exemestane11%Part D<11 patientsKinase inhibitor19.7%Kisqali43%Verzenio29%Ibrance15%Tukysa14%Part D<11 patients+ 1 more class in this area
Nervous system
4%Gabapentinoids4%Gabapentin100%Part D<11 patientsMetabolism & gastrointestinal
3.8%Serotonin-3 Receptor Antagonist3.8%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gut microbiota interact with breast cancer therapeutics to modulate efficacy
EMBO Molecular Medicine
2025 - Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review
Frontiers in Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Benjamin Moeller, MD, PhD
Levine Cancer Institute
Jubilee Brown, MD
Levine Cancer Institute
Robert Naumann, MD
Levine Cancer Institute
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”